Literature DB >> 22549349

Clinical characteristics of exacerbations in Parkinson disease.

Karen S Zheng1, Benjamin J Dorfman, Paul J Christos, Nasim R Khadem, Claire Henchcliffe, Panida Piboolnurak, Melissa J Nirenberg.   

Abstract

BACKGROUND: Episodes of subacute worsening of motor function occur commonly in Parkinson disease (PD), but there has been surprisingly little research about the clinical characteristics of these exacerbations in the outpatient setting.
METHODS: Retrospective study of an established cohort of 120 outpatients with PD. Primary outcome measures were the frequency, causes, and outcomes of motor exacerbations. Statistical analysis was performed to compare baseline characteristics of subjects with subsequent exacerbations versus without subsequent exacerbations.
RESULTS: Over an 18-month period, 43 exacerbations occurred, affecting 30 of 120 subjects (25.0%). Infection was the single most frequent underlying cause, accounting for 11 of 43 (25.6%) exacerbations. Other common etiologies were anxiety (n=8), medication errors (n=6), poor adherence (n=6), medication side effects (n=3), and postoperative decline (n=3). Overall, 35 episodes (81.4%) were attributable to reversible or treatable causes. Most subjects recovered fully, but 10 (33.3%) experienced recurrent episodes, 5 (16.7%) suffered permanent decline, and 1 died. At baseline, subjects with exacerbations had a significantly longer median disease duration (7.8 vs. 5.7 y, P=0.003), lower Mini-Mental State Examination scores (27.0±3.3 vs. 28.6±1.6, P=0.02), higher modified Hoehn and Yahr scores (2.2±0.5 vs. 1.9±0.5, P=0.006), greater dopaminergic medication use (median, 750.0 vs. 395.0 levodopa equivalents; P=0.009), and a greater prevalence of motor complications (55.2% vs. 29.4%, P=0.01) than subjects without exacerbations.
CONCLUSIONS: Exacerbations are common in PD, associated with more advanced disease, and usually attributable to treatable secondary causes such as intercurrent infection. Increased recognition of these underlying causes may help to decrease morbidity, reduce health care costs, and optimize quality of care in PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549349      PMCID: PMC3626090          DOI: 10.1097/NRL.0b013e318251e6f2

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  15 in total

Review 1.  Clinical practice. Diagnosis and initial management of Parkinson's disease.

Authors:  John G Nutt; G Frederick Wooten
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

Review 2.  Non-motor symptoms of Parkinson's disease: diagnosis and management.

Authors:  K Ray Chaudhuri; Daniel G Healy; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

Review 3.  Parkinson's disease: clinical features and diagnosis.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-04       Impact factor: 10.154

4.  Clinical predictors of frequent patient telephone calls in Parkinson's disease.

Authors:  Anli A Liu; Christine E Boxhorn; Michael A Klufas; Paul J Christos; Jeffrey T Thorne; Angela Y Shih; Nadejda M Tsankova; Benjamin J Dorfman; Claire Henchcliffe; Panida Piboolnurak; Melissa J Nirenberg
Journal:  Parkinsonism Relat Disord       Date:  2010-11-27       Impact factor: 4.891

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 6.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

7.  Dopamine agonist withdrawal syndrome in Parkinson disease.

Authors:  Christina A Rabinak; Melissa J Nirenberg
Journal:  Arch Neurol       Date:  2010-01

Review 8.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

9.  Autonomic dysfunction in dementia.

Authors:  L M Allan; C G Ballard; J Allen; A Murray; A W Davidson; I G McKeith; R A Kenny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

10.  Orthostatic hypotension in Parkinson's disease: association with cognitive decline?

Authors:  Liesl M Allcock; Rose Anne Kenny; Urs Peter Mosimann; Sherley Tordoff; Keith A Wesnes; Anthony J Hildreth; David J Burn
Journal:  Int J Geriatr Psychiatry       Date:  2006-08       Impact factor: 3.485

View more
  16 in total

1.  Peripheral viral challenge increases c-fos level in cerebral neurons.

Authors:  Tiffany J Petrisko; Gregory W Konat
Journal:  Metab Brain Dis       Date:  2021-08-18       Impact factor: 3.584

Review 2.  Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.

Authors:  Jeremy M Morowitz; Kaylyn B Pogson; Daniel A Roque; Frank C Church
Journal:  Brain Sci       Date:  2022-04-22

3.  Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum.

Authors:  Yue Huang; Cheng Chang; Jiewen Zhang; Xiaoqun Gao
Journal:  Neural Regen Res       Date:  2012-12-05       Impact factor: 5.135

4.  Risk of Parkinson's Disease Among Patients with Psoriasis: A Systematic Review and Meta-analysis.

Authors:  Patompong Ungprasert; Narat Srivali; Wonngarm Kittanamongkolchai
Journal:  Indian J Dermatol       Date:  2016 Mar-Apr       Impact factor: 1.494

5.  Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson's Disease Patients.

Authors:  Martin Klietz; Amelie Tulke; Lars H Müschen; Lejla Paracka; Christoph Schrader; Dirk W Dressler; Florian Wegner
Journal:  Front Neurol       Date:  2018-03-06       Impact factor: 4.003

6.  Self-Reported Nonadherence Predicts Changes of Medication after Discharge from Hospital in People with Parkinson's Disease.

Authors:  Francis Feldmann; Hannah M Zipprich; Otto W Witte; Tino Prell
Journal:  Parkinsons Dis       Date:  2020-07-04

7.  Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study.

Authors:  Atsushi Umemura; Tomoko Oeda; Satoshi Tomita; Ryutaro Hayashi; Masayuki Kohsaka; Kwiyoung Park; Hiroshi Sugiyama; Hideyuki Sawada
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

8.  Why is there motor deterioration in Parkinson's disease during systemic infections-a hypothetical view.

Authors:  Florian Brugger; Roberto Erro; Bettina Balint; Georg Kägi; Paolo Barone; Kailash P Bhatia
Journal:  NPJ Parkinsons Dis       Date:  2015-08-27

Review 9.  Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review.

Authors:  Takafumi Kubota; Naoto Kuroda
Journal:  Clin Neurol Neurosurg       Date:  2020-11-01       Impact factor: 1.876

10.  The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.

Authors:  Ethan G Brown; Lana M Chahine; Samuel M Goldman; Monica Korell; Emerald Mann; Daniel R Kinel; Vanessa Arnedo; Kenneth L Marek; Caroline M Tanner
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.